Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study

Overview of attention for article published in Frontiers in oncology, October 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 1 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 26,725 followers.

RT @DrImranSheikh: Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients…

12 Oct 2022

Reply Repost Favourite

RT @DrImranSheikh: Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients…

12 Oct 2022

Reply Repost Favourite

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study: Objective Immune checkpoint inhibitors (ICIs) have recently been increasingly used… #oncology https://t.co/vgr

10 Oct 2022

Reply Repost Favourite

New research: Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study: Objective Immune checkpoint inhibitors (ICIs) have recently been increasingly used… https://t.co

06 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.